| Issue Date | Title | Author(s) | Source | scopus | WOS | Fulltext/Archive link |
| 2020 | Globo H-KLH vaccine adagloxad simolenin (OBI-822)/OBI-821 in patients with metastatic breast cancer: phase II randomized, placebo-controlled study | CHIUN-SHENG HUANG ; Yu A.L.; Tseng L.-M.; Chow L.W.C.; Hou M.-F.; Hurvitz S.A.; Schwab R.B.; L Murray J.; Chang H.-K.; Chang H.-T.; Chen S.-C.; Kim S.-B.; Hung J.-T.; Ueng S.-H.; Lee S.-H.; Chen C.-C.; Rugo H.S. | Journal for immunotherapy of cancer | 26 | 25 | |
| 2021 | Matching-adjusted indirect comparison of ribociclib plus fulvestrant versus palbociclib plus letrozole as first-line treatment of hr+/her2? advanced breast cancer | Fasching P.A.; Delea T.E.; YEN-SHEN LU ; De Boer R.; Hurvitz S.A.; Moynahan A.; Chandiwana D.; Lanoue B.; Hu H.; Thuerigen A.; O��shaughnessy J. | Cancer Management and Research | 0 | 0 | |
| 2019 | Neoadjuvant trastuzumab emtansine and pertuzumab in human epidermal growth factor receptor 2–positive breast cancer: Three-year outcomes from the phase III KristinE study | Hurvitz S.A.; Martin M.; Jung K.H.; CHIUN-SHENG HUANG ; Harbeck N.; Valero V.; Stroyakovskiy D.; Wildiers H.; Campone M.; Boileau J.-F.; Fasching P.A.; Afenjar K.; Spera G.; Lopez-Valverde V.; Song C.; Trask P.; Boulet T.; Sparano J.A.; Fraser Symmans W.; Thompson A.M.; Slamon D. | Journal of Clinical Oncology | 131 | 112 | |
| 2018 | Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial | Hurvitz S.A.; Martin M.; Symmans W.F.; Jung K.H.; CHIUN-SHENG HUANG ; Thompson A.M.; Harbeck N.; Valero V.; Stroyakovskiy D.; Wildiers H.; Campone M.; Boileau J.-F.; Beckmann M.W.; Afenjar K.; Fresco R.; Helms H.-J.; Xu J.; Lin Y.G.; Sparano J.; Slamon D. | The Lancet Oncology | 288 | 267 | |
| 2020 | Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with ? 2 HER2-directed regimens: Phase III NALA trial | Saura C.; Oliveira M.; Feng Y.-H.; Dai M.-S.; Chen S.-W.; Hurvitz S.A.; Kim S.-B.; Moy B.; Delaloge S.; Gradishar W.; Masuda N.; Palacova M.; Trudeau M.E.; Mattson J.; Yap Y.S.; Hou M.-F.; De Laurentiis M.; Yeh Y.-M.; Chang H.-T.; Yau T.; Wildiers H.; Haley B.; Fagnani D.; YEN-SHEN LU ; Crown J.; Lin J.; Takahashi M.; Takano T.; Yamaguchi M.; Fujii T.; Yao B.; Bebchuk J.; Keyvanjah K.; Bryce R.; Brufsky A.; NALA Investigators | Journal of Clinical Oncology | 288 | 270 | |
| 2018 | Paclitaxel with inhibitor of apoptosis antagonist, LCL161, for localized triple-negative breast cancer, prospectively stratified by gene signature in a biomarker-driven neoadjuvant trial | Bardia A.; Parton M.; Kummel S.; Estevez L.G.; CHIUN-SHENG HUANG ; Cortes J.; Ruiz-Borrego M.; Telli M.L.; Martin-Martorell P.; Lopez R.; Beck J.T.; Ismail-Khan R.; Chen S.-C.; Hurvitz S.A.; Mayer I.A.; Carreon D.; Cameron S.; Liao S.; Baselga J.; Kim S.-B. | Journal of Clinical Oncology | 36 | 36 | |
| 2020 | Potent cell-cycle inhibition and upregulation of immune response with abemaciclib and anastrozole in Neomonarch, phase II neoadjuvant study in HR+/HER2- Breast cancer | Hurvitz S.A.; Martin M.; Press M.F.; Chan D.; Fernandez-Abad M.; Petru E.; Rostorfer R.; Guarneri V.; CHIUN-SHENG HUANG ; Barriga S.; Wijayawardana S.; Brahmachary M.; Ebert P.J.; Hossain A.; Liu J.; Abel A.; Aggarwal A.; Jansen V.M.; Slamon D.J. | Clinical Cancer Research | 107 | 106 | |
